Ahmed Salman

Dr. Ahmed Salman is a Senior Immunologist-Vaccinologist and Research Group Leader at the Jenner Institute, University of Oxford, affiliated with Kellogg College. He specializes in developing vaccines against infectious and cancerous diseases, focusing on malaria, COVID-19, and veterinary pathogens. His work employs advanced technologies like viral vectors, viral-like particles (VLPs), and CRISPR-based approaches. He holds a DPhil in Clinical Medicine from the University of Oxford, following degrees from Ain Shams University and collaborations with institutions like the Statens Serum Institut.

Research Interests: Dr. Salman’s research centers on identifying vaccine antigens, optimizing vaccine platforms, and advancing gene therapy for retinal diseases. His contributions include patents for malaria vaccines and pivotal roles in the Oxford-AstraZeneca COVID-19 vaccine development. He leads projects funded by the Bill & Melinda Gates Foundation and MRC, focusing on antigen selection for clinical trials.

Grants & Awards: His work has been supported by major funders, and he holds patents for malaria vaccine candidates. He is a member of the British Society for Immunology and American Society of Tropical Medicine and Hygiene.

Publications: His recent work spans malaria vaccine mechanisms, retinal immunology, and cybersecurity applications of AI. Contributions include studies on CRISPR delivery to the retina and AI frameworks for cybersecurity education.